Biotechnology company Cereno Scientific (Nasdaq First North:CRNO B) announced on Friday that the first patient has been dosed with CS1 under its Expanded Access Program (EAP) for Pulmonary Arterial Hypertension (PAH).
This program allows patients who completed the Phase II trial to continue receiving CS1 based on perceived benefit, as determined by both the patient and physician.
The EAP aims to gather extensive data on long-term CS1 usage, supporting future regulatory discussions and pivotal trial planning. Approved since January 30, 2024, the EAP is an extension of the Phase II trial under an FDA protocol.
CS1, an HDAC inhibitor targeting PAH, has shown potential in Phase II trials, with topline results expected in Q3 2024.
Johnson & Johnson submits DARZALEX FASPRO supplemental Biologics License Application to FDA
Modalis Therapeutics receives FDA Rare Pediatric Disease designation for MDL-101 in LAMA2-CMD
Adicet Bio announces enrollment for Phase 1 trial to evaluate ADI-001 in autoimmune diseases
Astria Therapeutics secures FDA Orphan Drug Designation for Nnavenibart in HAE treatment
Bristol-Myers Squibb's schizophrenia drug Cobenfy receives US FDA approval
Pharming receives UK marketing authorisation for Joenja
DURECT Corporation announces design of upcoming registrational Phase 3 larsucosterol trial
EydisBio's EYD-001 receives US FDA Orphan Drug Designation
Biocon BIologics unveils new dermatology data at EADV Congress 2024
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
NeuroSense Therapeutics receives US patent for novel PrimeC formulation
IntraBio's Aqneursa receives US FDA approval
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Elevation Oncology's EO-3021 receives US FDA Fast Track designation
Lantern Pharma secures FDA designations for rare paediatric cancers